1190P - Specificities of lung cancer in never-smoking women

Date 30 September 2012
Event ESMO Congress 2012
Session Poster presentation II
Topics Non-Small-Cell Lung Cancer, Early Stage
Cancer Aetiology, Epidemiology, Prevention
Presenter Julien Mazières
Authors J. Mazières1, I. Rouquette2, B. Lepage2, J. Milia2, P. Validire3, P. Hofman4, M. Beau-Faller5, L. Brouchet2, P. Fouret6
  • 1Thoracic Oncology, CHU Toulouse - Hôpital Larrey, 31400 - toulouse/FR
  • 2Thoracic Oncology, CHU Toulouse - Hôpital Larrey, 31000 - toulouse/FR
  • 3Pathology, Institut Mutualiste Montsouris, 75000 - PAris/FR
  • 4Pathology, CHU Nice, 06000 - Nice/FR
  • 5Pathology, CHU Strasbourg, 67000 - Strasbourg/FR
  • 6Pathologie, APHP-La Salpetrière, 75000 - PAris/FR



Based on epidemiological, clinical, and preclinical data, lung carcinogenesis can be distinctive in women. No clear data is available to help us understand the high rate of tobacco-independent lung cancer in women. We hypothesize that genetic events or hormonal factors might be partly involved in these tobacco-independent lung cancers.


We thus aimed to compare clinical, pathological and biological characteristics of lung cancer in two cohorts of smoking and never smoking women. A population of 140 women (63 never-smokers and 77 former or current smokers) carrying adenocarcinoma issued from our centre and a national collection has been included in this study.


The non-smoking population was characterized by a higher age (67yrs vs 58.7, p < 0.0001) and a higher frequency of a lepidic component (60.3% vs 37.7 %, p = 0.008) than the smoking patients. We observed a differential genetic alteration repartition in women according to their tobacco status: 50.8% of never-smokers displayed EGFR mutation vs. 10.4% of smokers (p < 0.001). At the opposite KRas mutation was more frequently mutated in smokers (33.8%) than in never-smokers (9.5%, p = 0.001). We also observed a higher percentage of ERα (p = 0.03 by using the breast cancer score) and ER� expression (p = 0.02) for non-smoking patients compared with smoking ones. We found no significant differences for progesterone receptors. Lastly ER expression was correlated with EGFR mutation.


This study suggests that lung cancer occurring in never-smoking women is more frequently associated with EGFR mutation and ER expression, with a correlation between both markers. These findings underline the possibility of therapy in non-smoking-women targeting both hormonal factors and genetic abnormalities.


All authors have declared no conflicts of interest.